Journal of cachexia, sarcopenia and muscle
The most recent articles from:
J Cachexia Sarcopenia Muscle
-
J Cachexia Sarcopenia Muscle · Dec 2020
Randomized Controlled TrialSafety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort.
Bimagrumab prevents activity of myostatin and other negative regulators of skeletal muscle mass. This randomized double-blind, placebo-controlled study investigated safety, pharmacokinetics (PK), and pharmacodynamics of bimagrumab in healthy older and obese adults. ⋯ Bimagrumab was safe and well tolerated and demonstrated similar PK in older and obese adults. A single dose of bimagrumab rapidly increased TMV and LBM and decreased body adiposity in older adults. Muscle hypertrophy and fat loss were sustained with extended drug exposure.